Because this oxidation is a multistep cascade, the clearance of methylation in these TF-binding regions is likely strongest in hematological malignancies with concomitant mutations in TET2 and DNMT3A that indeed are known synergistic drivers of neoplasia38. The gene discussed is TET2; the disease is hematologic disorder.